

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On June 16, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: Nicole Wartell

Nicole Wartell



PATENT
Attorney Docket No.: 020618-000600US
Client Reference No.: N9-59

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory S. Hageman

Application No.: 09/511,008

Filed: February 22, 2000

For: DIAGNOSTICS AND
THERAPEUTICS FOR ARTERIAL
WALL DISRUPTIVE DISORDERS

Examiner: Q. Janice Li

Art Unit: 1632

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98**


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no


**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

		Application Number	09/511,008
		Filing Date	February 22, 2000
		First Named Inventor	Hageman, Gregory S.
		Art Unit	1632
		Examiner Name	Q. Janice Li
Total Number of Pages in This Submission		Attorney Docket Number	020618-000600US

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group		
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences		
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information		
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter		
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of thirty-six (36) cited references		
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer			
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund			
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____			
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application				
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53				
<table border="1"> <tr> <td>Remarks</td> <td>The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.</td> </tr> </table>			Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Townsend and Townsend and Crew LLP	Reg. No. 42,271
Signature		
Date	6-16-04	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Nicole Wartell		
Signature		Date	6/16/04

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:nmb

60227154 v1



Substitute for form 1449A/PTO				Complete if Known	
				Application Number	09/511,008
				Filing Date	February 22, 2000
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1632
				Examiner Name	Q. Janice Li
Sheet	1	of	4	Attorney Docket Number	020618-000600US

U.S. PATENT DOCUMENTS+						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1					
	A2					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	PCT	WO 01/02866	A1	01-11-2001			<input type="checkbox"/>
	B2	PCT	WO 01/06262	A1	01-25-2001			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1764 (Rev. 1-2000) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/511,008
				Filing Date	February 22, 2000
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1632
				Examiner Name	Q. Janice Li
Sheet	2	of	4	Attorney Docket Number	020618-000600US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	ANIDJAR, S. et al. "Elastase-induced experimental aneurysms in rats" Circulation, Sept. 1990, pp. 973-981, Vol. 82, No. 3.		
	C2	Cobb et al. "Matrix Metalloproteinases and Their Inhibitors in Vitreous in Age-Related Macular Degeneration and Proliferative Diabetic Retinopathy" Investigative Ophthalmology and Visual Science Abstract Book- Part 1, March 1997, 1651 S354 Vol. 38, No. 4.		
	C3	COHEN, J.R. et al. "Role of the neutrophil in abdominal aortic aneurysm development" Cardiovasc. Surg., August 1993, pp. 373-376, Vol. 1, No. 4.		
	C4	COHEN, J.R. et al. "Urinary L-valyl proline in patients with aortic aneurysms" Surg. Gynecol. Obstet., June 1989, pp. 507-512, Vol. 168, No. 6.		
	C5	DEPALMA, R.G. et al. "Approaches to evaluating regression of experimental atherosclerosis" Adv. Exp. Med. Biol., 1977, pp. 459-470, Vol. 82.		
	C6	GINEITIS, A. et al. "Two-dimensional high-resolution electrophoresis of elastin-derived peptides" J. Chromatogr. B. Biomed. Sci. Appl., 9 May 1997, pp. 303-310, Vol. 692, No. 2.		
	C7	GOLDBERG, J. et al. "Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey" Am J. Epidemiol., Oct. 1988, pp. 700-710, Vol. 128, No. 4.		
	C8	HIRVELA, H. et al. "Risk factors of age-related maculopathy in a population 70 years of age or older" Ophthalmology, June 1996, pp. 871-877, Vol. 103, No. 6.		
	C9	HYMAN, L.G. et al. "Senile macular degeneration: a case-control study" Am. J. Epidemiol., August 1983, pp. 213-227, Vol. 118, No. 2.		
	C10	JUVONEN, T. et al. "Demonstration of a bioactive elastin-derived peptide (Val-Gly-Val-Ala-Pro-Gly) in vascular lesions characterized by the segmental destruction of media" Ann. Chir. Gynaecol., 1994, pp. 296-302, Vol. 83, No. 4.		
	C11	KLEIN, R. et al. "Early age-related maculopathy in the cardiovascular health study" Ophthalmology, Jan 2003, pp. 25-33, Vol. 110, No. 1.		
	C12	KLEIN, R. et al. "Prevalence of age-related maculopathy in the Atherosclerosis Risk in Communities Study" Arch. Ophthalmol., Sept, 1999, pp. 1203-1210, Vol. 117, No. 9.		
	C13	KLEIN, R. et al. "The relation of cardiovascular disease and its risk factors to the 5-year incidence of age-related maculopathy: the Beaver Dam Eye Study" Ophthalmology, Nov. 1997, pp. 1804-1812, Vol. 104, No. 11.		
	C14	KUIVANIEMI, H. et al. "Candidate genes for abdominal aortic aneurysms" Ann. NY Acad. Sci., Nov. 1996, pp. 186-197, Vol. 800.		
	C15	LINDHOLT, J.S. et al. "Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms" Eur. J. Vasc. Endovasc. Surg. July 1997, pp. 12-16, Vol. 14, No. 1.		

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/511,008
				Filing Date	February 22, 2000
				First Named Inventor	Hageman, Gregory S.
				Art Unit	1632
				Examiner Name	Q. Janice Li
Sheet	3	of	4	Attorney Docket Number	020618-000600US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C16	LOUWRENS, H.D. et al. "Risk factors for the atherosclerosis in men with stenosing or aneurysmal disease of the abdominal aorta" Int. Angiol., March 1993, pp. 21-24, Vol. 12, No. 1.			
	C17	MACSWEENEY, S.T. et al. "Pathogenesis of abdominal aortic aneurysm" Br. J. Surg., July 1994, pp. 935-941, Vol. 81, No. 7.			
	C18	MALINOW, M.R. & MARUFFO, C.A. "Naturally occurring atherosclerosis in howler monkeys (Alouatta caraya)" J. Atheroscler. Res., Jul-Aug. 1966, pp. 368-380, Vol. 6, No. 4.			
	C19	NACKMAN, G.B. et al. "Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model" Surgery, July 1997, pp. 39-44, Vol. 122, No. 1.			
	C20	NORRGARD, O. et al. "Familial aortic aneurysms: serum concentrations of triglyceride, cholesterol, HDL-cholesterol and (VLDL + LDL)-cholesterol" Br. J. Surg., Feb. 1985, pp. 113-116, Vol. 72, No. 2.			
	C21	NORRGARD, O. et al. "High concentrations of Lp(a) lipoprotein in serum are common among patients with abdominal aortic aneurysms" Int. Angiol., Jan-March 1988, pp. 46-49, Vol. 7, No. 1.			
	C22	SMITH, W. et al. "Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study" Arch. Ophthalmol. May 1998, pp. 583-587, Vol. 116, No. 5.			
	C23	SMITH, W. et al. "Risk factors for age-related macular degeneration: Pooled findings from three continents" Ophthalmology, April 2001, pp. 697-704, Vol. 108, No. 4.			
	C24	SPERDUTO, R.D. & HILLER, R. "Systemic hypertension and age-related maculopathy in the Framingham study" Arch. Ophthalmol., Feb 1986, pp. 216-219, Vol. 104, No. 2.			
	C25	STRICKLAND, H.L. & BOND, M.G. "Aneurysms in a large colony of squirrel monkeys (Saimiri sciureus)" Lab Anim. Sci., Dec. 1983, pp. 589-592, Vol. 33, No. 6.			
	C26	Tarkkanen and Laatikainen, "Late ocular manifestations in neonatal herpes simplex infection," Br. J. Ophthalmol., vol. 61, pages 608-616, 1977.			
	C27	THOMPSON, R.W. "Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem" Curr. Opin. Cardiol., Sept. 1996, pp. 504-518, Vol. 11, No. 5.			
	C28	TILSON, M.D. & STANSEL, H.C. "Differences in results for aneurysm vs occlusive disease after bifurcation grafts: results of 100 elective grafts." Arch. Surg., Oct. 1980, pp. 1173-1175, Vol. 115, no. 10.			
	C29	TILSON, MD, & NEWMAN, K. "Rationale for molecular approaches to the etiology of abdominal aortic aneurysm disease" J. Vasc. Surg., May 1992, pp. 924-925, Vol. 15, No. 5.			
	C30	VERLOES, A. et al. "Genetic aspects of abdominal aortic aneurysm." Ann. NY Acad. Sci., 18 Nov. 1996, pp. 44-55, Vol. 800.			
	C31	VINDING, T. et al. "Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiological study of 1000 aged individuals" Acta. Ophthalmol., Feb. 1992, pp. 66-72, Vol. 70, No. 1.			

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known
Application Number	09/511,008			
Filing Date	February 22, 2000			
First Named Inventor	Hageman, Gregory S.			
Art Unit	1632			
Examiner Name	Q. Janice Li			
Attorney Docket Number	020618-000600US			

Sheet

4

of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C32	WILMINK, A.B. & QUICK, C.R. "Epidemiology and potential for prevention of abdominal aortic aneurysm" Br. J. Surg., Feb. 1998, pp. 155-162, Vol. 85, No. 2.	
	C33	ZARINS, C.K. et al. "Aneurysm formation in experimental atherosclerosis: relationship to plaque evolution" J. Vasc. Surg., 1990, pp. 246-256, Vol. 12.	
	C34	ZARINS, C.K. et al. "Aneurysmal enlargement of the aorta during regression of experimental atherosclerosis" J. Vasc. Surg., Jan 1992, pp. 90-101, Vol. 15, No. 1.	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

JUN 18 2004

PTO/SB/17 (10-03)

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180)

Complete if Known	
Application Number	09/511,008
Filing Date	February 22, 2000
First Named Inventor	Hageman, Gregory S.
Examiner Name	Q. Janice Li
Art Unit	1632
Attorney Docket No.	020618-000600US

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account:

Deposit Account Number

20-1430

Deposit Account Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) or any underpayment of fee(s)
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity

Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Large Entity

Small Entity

Total Claims	-**	=	Extra Claims	Fee from below	Fee Paid
Independent Claims	-**	=			
Multiple Dependent	-**	=			
		X			

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)					
3. ADDITIONAL FEES	Large Entity	Small Entity	Fee Description	Fee Paid	
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify) _____					
*Reduced by Basic Filing Fee Paid					SUBTOTAL (3) (\$180)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Scott L. Ausenhus	Registration No. (Attorney/Agent)	42,271	Telephone	303-571-4000
Signature				Date	6-16-04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.